Insights and Developments in HIV Treatment Strategies

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-502-L02-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
 



Co-produced by ProCE, the Society of Infectious Diseases Pharmacists (SIDP), and the National Association of Specialty Pharmacy (NASP).   

Activity Description

Human immunodeficiency virus (HIV) research is undergoing an era of rapid change and advancement in treatment approaches. Historically complex drug regimens are being simplified, less-toxic alternative therapies are proving equally effective to older agents, and novel dosage forms on the horizon are expected to impact patient care and outcomes. Advances in therapeutic approaches have allowed patients living with HIV to lead fairly normal lives without the disease significantly interfering with quality of life and the potential to entirely halt progression. However, staying informed about the latest recommendations and newly available drugs and drug combinations is often challenging for many pharmacy professionals.

This session will discuss strategies to identify patients at risk for HIV and implement screening guideline recommendations. Current recommendations for treatment initiation and regimen selection in patients with co-morbidities or previous treatment failures will be discussed, including dosing and monitoring requirements. A focus on recently approved therapies and emerging treatment options will be presented. The activity will also address principles for PEP and PrEP prescribing and monitoring schedules.

 

Learning Objectives

The target audience for this activity includes clinical pharmacists, community pharmacists, specialty pharmacists, and managed care professionals. At the completion of this activity, the participant will be better able to:

  • Identify individuals at risk for HIV infection and outline screening guidelines.
  • Outline current guideline recommendations for Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) prescribing and monitoring schedule.
  • Examine therapy options for treatment naïve patients and antiretroviral therapy (ART) regimen selection for patients with treatment failure or comorbidities.
  • Discuss techniques to improve uptake and adherence to ART in patients with HIV.
  • Recognize recently approved and emerging pipeline agents for treatment of HIV and identify their place in therapy.

Faculty

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Professor of Clinical Pharmacy
UCSF School of Pharmacy
Pharmacist, UCSF Womens HIV Program
San Francisco, California

Jason J. Schafer, PharmD, MPH, BCPS AQ-ID, BCIDP, AAHIVP
Professor and Vice Chair
Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

CE Accreditation

Release Date: 12-09-2019
Expiration Date: 1-8-2021

Pharmacists

This activity is jointly provided by ProCE, Inc., the Society of Infectious Diseases Pharmacists, and the National Association of Specialty Pharmacy. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-502-H02-P has been assigned to this home study knowledge-based activity (initial release date 12-09-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Cocohoba has no relevant commercial or financial relationships to disclose. Dr. Schafer is an advisory board member for Merck, and has received research grant funding as a primary investigator for Gilead and Merck. A portion of grant funds received by ProCE from Merck and ViiV Healthcare will be used to compensate the faculty for this presentation.

Funding

This activity is supported by an educational grant from Merck and ViiV Healthcare.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.